NPM1 and acute myeloid leukemia: In the retrospective study by Rollig et al., a significant improvement in RFS was documented in the donor group, indicating a beneficial effect of alloHSCT in NPM1-mutated AML patients in first CR, also observed in the favorable subgroup without FLT3-ITD [78].